^
    Back
    Association details:
    Biomarker:KDR overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Oncol Rep
    Title:

    Potential of VEGFR2 expression as a predictive marker of PD‑1 blockade in patients with advanced NSCLC

    Published date:
    10/20/2022
    Excerpt:
    High VEGFR2 expression was a significant marker for predicting worse OS in patients treated with first‑line pembrolizumab, particularly in those with non‑AC.
    DOI:
    https://doi.org/10.3892/or.2022.8429